RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
CASI Pharma has reached a long-term agreement with a subsidiary of Shijiazhuang Yiling Pharma to manufacture two generic drugs, entecavir and cilostazol. In January of this year, CASI acquired rights to a 29-drug package of generics with abbreviated new drug applications from Sandoz, a Novartis subsidiary. CASI plans to market the drugs in China, the US and other global markets. CASI is headquartered in Maryland with R&D operations in Beijing.
Source: China Biotoday
